Efficacy and Safety of Cabozantinib for Advanced Gastrointestinal (GI) Neuroendocrine Tumors (NET) after Progression on Prior Therapy: Subgroup Analysis of the Phase 3 CABINET Trial (alliance A021602).
Journal of Clinical Oncology（2025）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined